Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Icon ( (ICLR) ) is now available.
On July 23, 2025, ICON plc announced the successful passing of all resolutions at its Annual General Meeting held on July 22, 2025. The resolutions included the re-election of board members, review of company affairs, and authorization of share allotments and purchases. This outcome reflects shareholder confidence in ICON’s strategic direction and governance, potentially strengthening its position in the clinical research industry.
The most recent analyst rating on (ICLR) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Icon stock, see the ICLR Stock Forecast page.
Spark’s Take on ICLR Stock
According to Spark, TipRanks’ AI Analyst, ICLR is a Outperform.
Icon’s overall stock score is driven by strong financial performance and moderate valuation. The company’s robust profitability and cash management are significant strengths. However, challenges highlighted in the earnings call, including revenue declines and elevated cancellations, weigh on the outlook. Technical indicators suggest positive short-term momentum but caution due to potential overbought conditions.
To see Spark’s full report on ICLR stock, click here.
More about Icon
ICON plc is a world-leading clinical research organization based in Dublin, Ireland, specializing in providing outsourced services to pharmaceutical, biotechnology, medical device, government, and public health organizations. The company focuses on advancing clinical research from molecule to medicine, driving innovations and emerging therapies, and improving patient lives. As of June 30, 2025, ICON employed approximately 39,900 employees across 95 locations in 55 countries.
Average Trading Volume: 1,521,726
Technical Sentiment Signal: Sell
Current Market Cap: $13.04B
For an in-depth examination of ICLR stock, go to TipRanks’ Overview page.